Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Inclusion Criteria: * Documentation of disease as assessed by the Alliance reference laboratory at the Ohio State University per Cancer and Leukemia Group B (CALGB) 20202, molecular diagnosis of core-binding factor (CBF) acute myeloid leukemia (AML) by reverse transcriptase polymerase chain reaction (RT-PCR) positive for RUNX1-RUNX1T1 fusion transcript resulting from t(8;21)(q22;q22) (or a variant form) or CBFB-MYH11 fusion transcript resulting from inv(16)(p13.1q22) or t(16;16)(p13.1;q22) (any % bone marrow or blood blasts render the diagnosis of CBF AML based on the World Health Organization \[WHO\] classification) * No prior chemotherapy for leukemia or myelodysplasia with the following exceptions: * Emergency leukapheresis * Emergency treatment for hyperleukocytosis with hydroxyurea, * Cranial radiotherapy (RT) for central nervous system (CNS) leukostasis (one dose only), * Growth factor/cytokine support/non-cytotoxic molecular-targeted agents * AML patients with a history of antecedent myelodysplasia (MDS) remain eligible for treatment on this trial * Patients who have developed therapy related myeloid neoplasm (t-MN) after prior radiation therapy or chemotherapy for another cancer or disorder are eligible * Left ventricular ejection fraction \>= lower limit of institutional normal by multigated acquisition (MUGA) or echocardiogram (ECHO) scan * Patients must not have had myocardial infarction within 6 months of registration * Patients must not have had ventric…